Drug Trial Radar · NCT05104125
Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Jan 12, 2022
Primary completion
Apr 10, 2023
Study completion Apr 10, 2023
Sponsor
- Lead sponsor
- Ascletis Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. The subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day according to the requirements of clinical trial scheme.
Conditions
- Acne Vulgaris
Interventions
ASC40 25mgDrug
25mg of ASC40 orally once daily for 12 weeks.
ASC40 50mgDrug
50mg of ASC40 orally once daily for 12 weeks.
ASC40 75mgDrug
75mg of ASC40 orally once daily for 12 weeks.
PlaceboDrug
Placebo orally once daily for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change of total lesion count compared with baseline and week 12.Time frame: Baseline to week 12
- Ratio of subjects, whose IGA grades was decreased by ≥2 grades compared with baseline at week 12.Time frame: Baseline to week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.